Background The role of thrombolytic agents in the treatment of pulmonary thromboembolism
(PTE) remains a controversial issue. The objective of this study is to assess the efficacy and …

Purpose Current literature on clinical controversies surrounding the use of thrombolytic
agents in patients with intermediate-risk pulmonary embolism (PE) is reviewed. Summary …

Objectives: We sought to assess the efficacy and safety of thrombolytic therapy in patients
with an acute pulmonary embolism (PE). Background: Thrombolytic therapy is approved for …

Background: Thrombolytic agents and anticoagulants are the two classes of medication
used in the treatment of acute pulmonary embolism (PE). There is continuous renewal and …

Pulmonary embolism (PE) is a common disorder that is accompanied by significant
morbidity and mortality. Although anticoagulation is the standard treatment for PE …

Background Thrombolytic therapy is usually reserved for patients with clinically serious or
massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may …

Recent guidelines recommend bolus-dose alteplase for treating massive pulmonary
embolism (PE). However, the safest and most effective treatment is as yet unknown. In the …

Background Thrombolytic therapy is usually reserved for people with clinically serious or
massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may …

Acute pulmonary embolism represents a major complication of venous thromboembolism
that is associated with high morbidity and mortality. Guidelines recommend the rapid …

Background The use of thrombolytic therapy in patients with intermediate-risk pulmonary
embolism is controversial. To compare with anticoagulation alone, no analysis before has …